» Articles » PMID: 39711772

Vitamin D Deficiency and Secondary Hyperparathyroidism in Adult Fontan Patients

Abstract

Background: The prevalence of vitamin D deficiency and secondary hyperparathyroidism (sHPT) in adult Fontan patients remains unstudied, and the role of vitamin D and parathyroid hormone (PTH) levels in assessing heart and circulatory failure in these patients is unclear.

Methods: We compared vitamin D deficiency and sHPT prevalence in adult Fontan patients (n = 35; mean age 33 ± 7.5 years) to adults with mild congenital heart disease (ACHD, n = 14). We analyzed associations between laboratory measurements, patient characteristics, and clinical events.

Findings: Vitamin D deficiency was highly prevalent in both Fontan patients and ACHD controls (76.5 % vs. 71.4 %, p = 0.726). sHPT was exclusively present in Fontan patients (31.4 %). PTH levels correlated with NYHA class (r = 0.412), O2 saturation (r = -0.39), systemic ventricular function (r = 0.465), and NT-proBNP levels (r = 0.742). 25-hydroxyvitamin D showed an inverse correlation with NYHA class and systemic ventricular function (both r ≤ -0.38). Fontan patients with sHPT had a higher incidence of prior hospitalization for worsening heart failure and atrial arrhythmias compared to Fontan patients without HPT or ACHD controls. (Hospitalization: Fontan with HPT vs. Fontan without HPT: OR 5.46 [95 % CI 1.25-23.86], p = 0.021; arrhythmia: Fontan with HPT vs. Fontan without HPT: OR 1.96 [95 % CI 1.13-3.4], p = 0.035; ACHD: OR 11.45 [95 % CI 1.7-77.28], p=<0.001). PTH showed significant correlation with inflammatory markers, particularly with GDF-15 (r = 0.8).

Conclusion: Our study is the first to demonstrate a high prevalence of vitamin D deficiency and sHPT in adult Fontan patients. As PTH strongly correlates with heart failure severity, it seems to be a promising biomarker in Fontan patients.

Citing Articles

Prevalence of Vitamin D deficiency among individuals with Fontan palliation: A systematic review and meta-analysis.

Khansa F, Ichwan C, Ghifari M, Daffa M, Nadia F, Zulfa P Ann Pediatr Cardiol. 2025; 17(5):313-319.

PMID: 39830494 PMC: 11737627. DOI: 10.4103/apc.apc_184_24.

References
1.
Holler F, Hannes T, Germund I, Emmel M, Hoyer-Kuhn H, Khalil M . Low serum 25-hydroxyvitamin D levels and secondary hyperparathyroidism in Fontan patients. Cardiol Young. 2015; 26(5):876-84. DOI: 10.1017/S1047951115001444. View

2.
Wu C, Kato T, Pronschinske K, Qiu S, Naka Y, Takayama H . Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail. 2012; 14(12):1356-65. PMC: 3598377. DOI: 10.1093/eurjhf/hfs138. View

3.
Wollert K, Kempf T, Wallentin L . Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017; 63(1):140-151. DOI: 10.1373/clinchem.2016.255174. View

4.
Passeri E, Rigolini R, Costa E, Verdelli C, Arcidiacono C, Carminati M . Serum NT-proBNP Levels Are Not Related to Vitamin D Status in Young Patients with Congenital Heart Defects. Dis Markers. 2016; 2016:3970284. PMC: 4756139. DOI: 10.1155/2016/3970284. View

5.
Rabenberg M, Mensink G . Vitamin D status of adults in Germany. J Health Monit. 2023; 1(2):34-40. PMC: 9838575. DOI: 10.17886/RKI-GBE-2016-042. View